Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Amy S. Clark(Abramson Center for Jewish Life), Laura J. Esserman(University of California, San Francisco), Rita Nanda(University of Chicago), Denise M. Wolf, Richard B. Schwab(Center for Personalized Cancer Treatment), Andres Forero‐Torres(Kirklin Clinic), Laura van ‘t Veer, Barbara Haley(Shaanxi Research Association for Women and Family), Erin D. Ellis(University of Hawaii Cancer Center), Adam L. Asare(Quantum Leap Healthcare Collaborative), Erin Roesch(University of California San Diego), Michael Alvarado(University of California, San Francisco), Scott Berry(Queen's University), Lamorna Brown Swigart(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Amy Wilson(Quantum Leap Healthcare Collaborative), Julia Wulfkuhle(University of California, San Francisco), Cheryl A. Ewing(University of California, San Francisco), Rachel L. Yung(Seattle Cancer Care Alliance), Teresa Helsten(University of California, San Diego), Ruby Singhrao(University of California, San Francisco), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Erin P. Crane(Georgetown University), Katherine Steeg(University of California, San Francisco), Julie E. Lang(University of Southern California), Julia L. Clennell(Berry & Associates (United States)), Stacy L. Moulder(The University of Texas MD Anderson Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Meredith Buxton(Center for Effective Global Action), A. Jo Chien(University of California, San Francisco), Rosa I. Gallagher(The University of Texas MD Anderson Cancer Center), Hyo S. Han(Moffitt Cancer Center), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Jeffrey B. Matthews(University of California, San Francisco), Kathleen Kemmer(University of Michigan), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Melissa Paoloni(National Institutes of Health), Ashish Sanil(Berry & Associates (United States)), Michelle Melisko(University of California, San Francisco), Debu Tripathy(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 73
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k